U.S. Pharma Races to License Chinese Biotech Innovations
Tap title to read story
A growing trend shows U.S. biopharmaceutical companies increasingly sourcing drugs from China, driven by cost efficiency and innovation. Summit Therapeutics recently made headlines by licensing a promising cancer drug from China's Akeso Inc., which outperformed Merck's Keytruda in trials. This shift is fueled by Chinese firms' ability to develop high-quality molecules and conduct early-stage trials at lower costs. Venture funding in China has dwindled, prompting more licensing deals. As major pharmaceutical companies like Gilead and Bain Capital engage more with Chinese biotechs, concerns arise about the impact on U.S. startups, though some see potential for reduced drug prices.
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.













